NEI Research News

Research team has identified advanced preclinical candidates targeting the bisretinoid synthesis pathway, which could help treat macular degeneration and Stargardt disease.

Using a new stem-cell based model made from skin cells, scientists found the first direct evidence that Stargardt-related ABCA4 gene mutations affect a layer of cells in the eye called the retinal pigment epithelium (RPE).

NEI researcher Mitra Farnoodian Tedrick, Ph.D., received a $65,000 grant from the Knights Templar Eye Foundation (KTEF) to identify drugs to treat a rare blinding condition called Stargardt disease.

A new study reveals how photoreceptors grown from stem cells might extend biological wires, known as axons, to contact existing neurons.

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.

National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.

Understanding the key structural determinants of a highly specialized membrane in the eye could lead to new treatments.

The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease Study 2 (AREDS2).

Researchers at Case Western Reserve University have used a unique method to safely deliver gene therapy to fight a rare, but irreversible, genetic eye disorder known as Stargardt disease.

Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of blinding retinal diseases.